Integrated Aesthetic Dentistry in NYC

The goal of Integrated Aesthetic Dentistry’s new website is to serve as an online resource where patients and colleagues can turn to for up-to-the-minute information and advice for all their oral health needs.

NEW YORK (PRWEB)
January 14, 2020

Leading New York City prosthodontics practice Integrated Aesthetic Dentistry has relaunched its website with a new and improved Hybrid-Responsive™ design at https://www.iadentistry.com.

Integrated Aesthetic Dentistry uses state-of-the-art technology to serve its patients and now the practice has a state-of-the-art website to match. Whether at work, at home, or on-the-go, patients will be able to easily access the information they need from a website that is responsive on smartphones, computers, and tablets. With comprehensive information about the practice, its prosthodontic services, and aftercare instructions, and its doctors all in one place, the Hybrid-Responsive site enables patients to play a more active role in managing their oral health.

“The goal of Integrated Aesthetic Dentistry’s new website is to serve as an online resource where patients and colleagues can turn to for up-to-the-minute information and advice for all their oral health needs,” says Integrated Aesthetic Dentistry’s founder, Dr. Caroline Barsoum. “We aim to produce original content of interest to our patients, colleagues and the local community who are committed to learning more about the importance of good oral health habits while having the opportunity to familiarize our practice with the community at large.”

About the Dentists

Dr. Caroline Barsoum earned her DMD from Tufts University School of Dental Medicine and her certificate in Prosthodontics from the Albert Einstein College of Medicine at Montefiore Hospital.

Dr. Michael J. Cafarella received his DMD from Tufts University School of Dental Medicine and his certificate in Prosthodontics from the Albert Einstein College of Medicine at Montefiore Hospital.

Dr. E. Lisa Reid earned her DMD from the University of Pennsylvania School of Dental Medicine and her certificate in Prosthodontics at the University of Iowa.

Dr. Mariam Habib received her DDS degree at the University of Tennessee before completing a general practice residency at St. Joseph’s Hospital in Patterson, NJ.

Dr. Priscilla Silva received her DDS degree from Universidad Iberoamericana. She received additional training and certification in general dentistry from Columbia University.

About Integrated Aesthetic Dentistry

Integrated Aesthetic Dentistry provides advanced prosthodontic services to improve both the function and appearance of patients’ teeth. To learn more or request an appointment, call 212-533-6782, visit the new website at https://www.iadentistry.com/, or stop by one of its 4 New York City locations:

Greenwich Village: 131 Macdougal Street New York, NY 10012

Gramercy Park: 130 E. 18th St. Ste 1M New York, NY 10003

Upper East Side: 185 E. 85th St. Office 2 New York, NY 10028

Park Avenue: 17 Park Ave New York, NY 10016

Share article on social media or email:

Xtalks Life Science Webinars

This webinar will appeal to individuals working at companies with molecules in late Phase 1 or Phase 2, or in need of advanced dose form for life cycle management purposes.

TORONTO (PRWEB)
January 13, 2020

In 2018, the US Food and Drug Administration (FDA) released updated guidelines on drug development. That same year, the European Medicines Agency (EMA) also took the initiative to implement additional regulations supporting drug development in Europe. Since the release of these guidelines, overlooking factors such as acceptability, excipient considerations and caregiver instructions are no longer an option.

On Wednesday, January 29, 2020 at 11am EST (4pm GMT/UK), join Matt Ling, Ph. D., Director of Scientific Services, at Catalent and Rachel Meyers, Pharm D., BCPS, BCPPS, FPPA, Clinical Associate Professor at Ernest Mario School of Pharmacy, Rutgers University and Pediatric Clinical Pharmacist, Saint Barnabas Medical Center for a live webinar where they will discuss:

• 
  The impact of age-appropriate dose forms for pediatrics
• Insights into caregiver perspectives
• A case study on real-world medications and acceptability assessment
• Solutions that address the challenges of pediatric drug development
• Factors in excipient decision-making
• Technologies for creating ideal dose forms

This webinar will appeal to individuals working at companies with molecules in late Phase 1 or Phase 2, or in need of advanced dose form for life cycle management purposes.

A live Q&A session with the speakers will follow the presentation.

Dr. Matt Ling has over 20 years’ experience in the pharmaceutical industry, much of this gained in big pharma, with roles in analytical, formulation development, advanced drug delivery and project leadership spanning all phases of discovery and development.

Dr. Meyers provides both didactic and experiential education in pediatric pharmacotherapy for pharmacy students and residents in her current position at Rutgers. She practices in the pediatric intensive care unit and the general pediatric unit at Saint Barnabas Medical Center.

For more information or to register for this event, visit Age-Appropriate Formulation Development for Pediatric Trials: Challenges and Considerations.

ABOUT CATALENT

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

From left to right, Dr. Davide Capodanno (M.D., Ph.D.), Dr. Gilles Montalescot (M.D., Ph.D.), Dr. Marco Valgimigli (M.D., Ph.D.), and Dr. Dirk Sibbing (M.D.).

“Spartan’s CYP2C19 test is a great tool because it is easy to perform and provides results in one hour. This enables the healthcare team to make rapid, precise treatment decisions leading to better patient outcomes,” said Jurrien M ten Berg, MD, PhD, FESC, FACC principal investigator of POPular Gene

OTTAWA, Ontario (PRWEB)
January 13, 2020

Spartan Bioscience, a world leader in precision medicine diagnostic solutions, announced today that it has established a new Scientific Advisory Board (SAB) in Europe. The SAB is comprised of a distinguished group of international clinical and academic Interventional Cardiology experts who will advise and support Spartan on its current and future clinical programs and product roadmap.

This SAB will be supplemented with a North American team to be announced at the American College of Cardiology (ACC) conference in March 2020.

The Spartan European SAB members are as follows:

• 
  Dirk Sibbing, M.D., Interventional Cardiologist and Professor of Cardiology, Ludwig-Maximilians University, Munich, Germany. Chair of the ESC Thrombosis Working Group.
• Gilles Montalescot, M.D., Ph.D., Professor of Cardiology at the University of Paris VI, and the Director of the Cardiac Care Unit, Pitié-Salpêtrière Hospital, Paris, France. Director of the INSERM unit on Thrombosis and Chairman of the ACTION (Allies in Cardiovascular Trials, Initiatives and Organized Networks) study group.
• Marco Valgimigli, M.D., Ph.D., Associate Professor of Cardiology and senior Interventional Cardiologist, Inselspital Universitätsspital, Bern, Switzerland. Acting chair of the European update guideline on DAPT.
• Davide Capodanno, M.D., Ph.D., Associate Professor of Cardiology, University of Catania and Interventional Cardiologist, Azienda “Policlinico-Vittorio Emanuele”, Catania, Italy. Associate Director of TCT and Editor-in-Chief of Eurointervention.

Spartan’s precision medicine test identifies whether or not a patient carries a CYP2C19 mutation. Over 30% of the world’s population, and 50% of Asians, carry CYP2C19 mutations. CYP2C19 is a liver enzyme that metabolizes 15% of all prescribed drugs, including antiplatelet drugs. Spartan’s rapid, portable test allows real-time, near patient determination of the patient’s genotype, aiding in determining the appropriate antiplatelet treatment leading to better patient results and lower cost healthcare.

The Spartan technology has been used in several landmark clinical studies including, POPular Genetics, a 2,500 patient, 8-year study in Europe published in the New England Journal of Medicine (NEJM), and announced at the European Society of Cardiology (ESC).(8) In addition, Spartan was used in TAILOR-PCI, a 5,300 patient, 7-year study funded by Mayo Foundation and the National Institutes of Health (NIH). TAILOR-PCI is the largest trial of genetics in cardiology and results are scheduled to be announced at the American Cardiology Association (ACC) conference in March 2020.

About Spartan Bioscience

Spartan Bioscience is the leader in on-demand DNA testing. (10) Spartan is bringing complete sample-to-result DNA testing systems to medicine. Spartan’s technology fully integrates DNA collection, extraction, and analysis, with an intuitive interface that is easy to operate. In the same way that mainframe computers gave way to personal computers, high-throughput DNA testing systems in central labs are giving way to decentralized devices. For the first time, healthcare providers and their patients can get DNA results on demand. For more information, please visit our website at: http://www.spartanbio.com.

The Spartan logo is a registered trademark of Spartan Bioscience Inc.

Plavix is a registered trademark of Bristol-Myers Squibb/Sanofi Pharmaceuticals.

Media Contact

Molly Kett, Director of Communications & Marketing

molly.kett@spartanbio.com

1. Damani SB, Topol EJ. (2010). J Am Coll Cardiol. 56:109–11.

2. Chen M et al. (2011). Atherosclerosis. 220(1):168–71.

3. Oh IY et al. (2012). Heart. 98(2):139–44.

4. Jose R et al. (2004). Fundamental & Clinical Pharmacology. 19(1): 101–105.

5. Dayoub EJ. (2018). JAMA Intern Med. 178(7): 943–950.

6. Mega JL et al. (2009). N Engl J Med. 360: 354–62.

7. Wiviott SD et al. (2007). N Engl J Med. 357: 2001–2015.

8. Claassens DMF et al. (2019). N Engl J Med. 381(17): 1621–1631.

9. dbSNP Short Genetic Variations. Reference SNP (refSNP) Cluster Report: rs12248560

10. Roberts JD et al. (2012). Lancet. 379:1705–11.

Share article on social media or email:

Stratus Video

Telehealth services have previously been unavailable to the limited English proficiency population. Through Stratus Video’s interoperability with Zoom, LEP patients can now receive equitable care.

CLEARWATER, Fla. (PRWEB)
January 13, 2020

Stratus Video, an industry leader in innovative language services, announced today that they have teamed up with Zoom Video Communications, a video-first unified communications platform. The technology interop between Stratus Video and Zoom allows healthcare providers to add medically qualified interpreters to telehealth calls with patients who do not speak English. This program is up and running at Novant Health, a not-for-profit, integrated healthcare system that handles more than 200,000 LEP encounters annually. This communication solution will help Novant Health and other healthcare facilities across the nation to achieve health equity for their LEP patients.

The Stratus Video technology platform is encrypted and HIPAA compliant, making it a natural complement to Zoom’s exemplary telehealth solution. The Zoom unified communications platform supports multi-party video calls, making it easy for Stratus Video interpreters to join and facilitate conversations between LEP patients and their healthcare providers. Telehealth helps to save time and effort, and reduces the risk of hospital-born infections that patients may be exposed to during follow-up visits. Telehealth services have previously been unavailable to the LEP population, but through this interoperability LEP patients can now reap the same telehealth benefits as English speaking patients.

“We were thrilled to roll out this integration across our hospitals and clinics,” said Pedro Mendez, Director Corp Language and Cultural Services at Novant Health, “LEP patients deserve the same level of care that English speakers receive, and this partnership gets us one step closer to providing completely equitable care.”

“We are excited to help bring telehealth services to the LEP population,” said David Fetterolf, Stratus Video President.

To learn more about Stratus Video products and services, visit http://www.stratusvideo.com.

About Stratus Video

Stratus Video offers technology enabled access to its medically qualified/certified interpreters to improve patient safety and care across the care continuum. A suite of offerings including audio, video and geo-location mobile applications along with inter-operability to telehealth solutions, provides language access when and where it’s needed. Led by a team of dedicated individuals, Stratus Video is committed to enabling Visual Connections and Vital Conversations. For more information, visit http://www.stratusvideo.com.

Share article on social media or email:

About 50 to 75 percent of all pregnant women take at least one prescription medication during pregnancy. However, of all the medications they use, less than 10 percent have been properly evaluated for safety. This should be of great concern to all of us.

LOS ANGELES (PRWEB)
January 13, 2020

Pregistry, LLC, an emerging leader in the development and execution of post-approval studies to assess the safety of medications and vaccines used during pregnancy and lactation, announced that it has been recognized with an award by Global Health & Pharma, a leading publication and information sharing platform, dedicated to the healthcare industry.

Pregistry was recognized as the “Best Pregnancy & Lactation Information Platform” in the 2019 Healthcare & Pharmaceutical Awards category of Global Health & Pharma. The Healthcare & Pharmaceutical Awards recognize visionary companies and individuals for harnessing disruptive ideas which will drive the healthcare and pharmaceutical industries forward. Pregistry has developed one of the world’s largest communities of pregnant and breastfeeding women with the goal to conduct observational research on the safety of medicines and vaccines used during pregnancy. Over 600,000 pregnant and nursing women are in Pregistry’s ever-growing pool, drawn in by the useful and practical information and tools that are offered online and without charge. Ultimately, this means that Pregistry is in the perfect position to send out surveys, analyze the responses, and communicate the findings on behalf of pharmaceutical companies, academia, and regulators.

Pregistry has an interesting business model. It exists simultaneously for the benefit of the pharmaceutical industry and, more specifically, for companies that have products that will likely be used by women of childbearing potential, and for pregnant women who receive useful information and tools. “Usually, we get involved during the drug’s phase III activities,” says Dr. Diego Wyszynski, CEO of Pregistry, “although it is not uncommon for us to be asked to consult during phase II of development. Predictably, most large studies we conduct, such as pregnancy exposure registries and analyses of administrative databases, occur when the drug is already on the market.”

“Our mission is to fill a major gap in information about the risks of medicines and vaccines during pregnancy and lactation to help women and their health care providers make informed, evidence-based health care decisions that optimize maternal and infant outcomes,” said Dr. Wyszynski. “For the last six years, we have worked extensively to develop and offer a large amount of information and tools free of charge, including expert reports on thousands of medications, exposures, and medical conditions. These expert reports can be saved and shared easily. Also, on pregistry.com our maternal health experts are available to answer questions 24/7. And, to facilitate communication among pregnant women, we have fantastic social forums that attract thousands of people every week.”

An interview with Dr. Wyszynski can be found here: https://www.ghp-news.com/issues/q4-2019/13/

To learn more about Pregistry, its communities, or services to the pharmaceutical industry, please visit https://www.pregistry.com.

About Pregistry, LLC

Pregistry is an emerging global leader in the development and execution of observational studies to assess the safety of medications and vaccines when used during pregnancy and lactation. With over 40 pregnancy specialists, covering a range of clinical, preclinical, safety, regulatory, marketing, and IT needs, the focus is on making sure that both mother and baby are healthy and safe and that prescribers have the information needed to be able to explain the potential benefits and risks of medications during pregnancy and lactation. To learn more, please visit: https://www.pregistry.com.

About Global Health & Pharma

GHP is a global information sharing platform & multi-disciplinary members community established to enhance communication & collaboration across Human, Animal and Environmental Health. Global Health & Pharma Magazine is the go-to resource on developing issues in healthcare and pharmaceuticals for over 260,000 wellness professionals and healthcare-related suppliers across four continents. Our informed readership includes individuals at all levels of their respective industries, from CEOs to healthcare professionals, nurses and support service workers. To learn more, please visit https://www.ghp-news.com.

About Global Health & Pharma Awards

When it comes to handing out recognition and awards, we believe there are few more deserving than those whose dedication changes the lives of millions of people every day. Our awards recognize innovation and courage in all aspects of the healthcare and pharmaceutical industries, including practitioners, scientists, nurses, architects, product designers, legal specialists and corporate decision makers. We believe all these roles are responsible for the life-changing innovations we see daily. To learn more, please visit https://www.ghp-news.com/awards.

Media Contact:

AK Parks

hello@pregistry.com

Share article on social media or email:

William Moore, M.D.

ARLINGTON, Texas (PRWEB)
January 13, 2020

Dr. Moore is board-certified in pain medicine and practices interventional pain management in Fort Worth and Arlington, Texas. His main focus is on treatment of the spine. In his practice, he utilizes a wide range of endoscopic spine procedures and minimally invasive techniques to treat neck and back pain.

Born in Laredo, this Texas native earned his Bachelor of Arts in Business Administration from Trinity University in San Antonio. He went on to earn his medical degree at the University of Texas Health Science Center at San Antonio, followed by a residency in Anesthesiology at Ochsner Clinic Foundation Hospital in New Orleans. Dr. Moore then went on to complete his fellowship training in Pain Medicine and Interventional Pain Management at Texas Tech University Health Science Center in Lubbock.

Dr. Moore has always been intrigued by interventional pain management and its dynamic quality. “It’s an area of extreme innovation,” he says. “In the past, spine treatment involved non-invasive physical therapy or a large surgical intervention. There was not a place in the middle that could affect a patient’s quality of life. Now, new developments allow minimally invasive access to specific nerves, joints and discs with very small incisions and a short recovery time. They provide a dramatic change in patients’ wellbeing.”

Dr. Moore joined PPOA from Capstone Pain and Spine Center, with three locations in the Dallas-Fort Worth area. Prior to joining Capstone and PPOA, he served as an assistant professor in the Pain Management/Anesthesiology Department at Texas Tech University Health Science Center, International Pain Institute.

He is a member of the American Society of Interventional Pain Physicians, the North American Spine Society, Texas Pain Society, Texas Medical Association and the Tarrant County Medical Society.

About PPOA:

Physician Partners of America (PPOA) is a national healthcare organization focused on strengthening the doctor-patient relationship, improving patient outcomes and leading the fight against the opioid crisis. Founded in 2013 and headquartered in Tampa, Fla., PPOA and its affiliates share a common vision of ensuring the wellbeing of patients through interventional and minimally invasive treatments, pain management and laser spine procedures. Its model allows its physician partners to focus on caring for patients in the face of increasingly complex administrative requirements. For more information about Physician Partners of America, visit http://www.physicianpartnersofamerica.com.

Share article on social media or email: